Salix Pharmaceuticals, Ltd. Stock

Stocks

15-03-16	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
15-03-16	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
15-03-16	Wall St. bounces as dollar drops, Fed worries ease	RE
15-03-16	Endo : withdraws offer for Salix	RE
15-03-11	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-02-24	Shire : buys Meritage Pharma for at least $70 million	RE
15-02-23	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
15-02-23	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
15-02-23	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
15-02-21	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

15-03-11	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
15-03-02	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
15-02-28	Salix Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information	BU
15-02-27	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
15-02-26	SALIX PHARMACEUTICALS : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU

15-04-01	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
15-03-30	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
15-03-16	Le recul du dollar a favorisé le rebond de Wall Street
15-03-16	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
15-03-16	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	2017-12-31
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	+0.03%	-1.09%	+61.59%	+22.26%	317B
MERCK KGAA	+0.16%	+1.61%	+39.05%	-9.12%	72.72B
HALOZYME THERAPEUTICS, INC.	+2.60%	+2.95%	+37.61%	+102.22%	10.17B
KYOWA KIRIN CO., LTD.	+1.29%	-0.31%	-5.23%	-4.32%	8.31B
SK BIOPHARMACEUTICALS CO., LTD.	+1.83%	+7.60%	-17.73%	-13.29%	4.6B
YUHAN CORPORATION	+3.60%	+5.14%	-32.05%	+11.14%	4.08B
BETTA PHARMACEUTICALS CO., LTD.	+3.02%	+10.06%	-11.26%	+24.85%	3.83B
SUPERNUS PHARMACEUTICALS, INC.	-0.32%	+2.52%	+10.18%	+45.31%	2.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.27%	-2.97%	-5.09%	-6.49%	2.16B
Average	+0.89%	+1.71%	+8.56%	+19.17%	47.29B
Weighted average by Cap.	+0.20%	-0.39%	+52.79%	+17.82%

Employees

Sector